HIV-associated opportunistic infections
When HIV wears down the immune system, germs that rarely harm healthy people cause severe disease. The CD4 count predicts which ones, and many can be prevented.
What it is
Infections that take hold, or become far more severe, because HIV has depleted CD4 T cells. Each appears below a typical CD4 threshold; several are AIDS-defining. They are prevented by antiretroviral therapy (ART), targeted prophylaxis below set CD4 levels and screening, and prophylaxis stops once ART restores the count.
Who gets it
Most people living with HIV in Colombia who develop an opportunistic infection were diagnosed late or are not on effective ART. Tuberculosis is the leading opportunistic infection and cause of death worldwide; in Latin America, disseminated histoplasmosis is a frequent AIDS-defining illness that is often mistaken for TB, and cryptococcal meningitis and cerebral toxoplasmosis (with high Toxoplasma seroprevalence) remain common.
Causes
- Any CD4 count: tuberculosis, bacterial pneumonia (pneumococcus), herpes zoster, syphilis, Kaposi sarcoma (HHV-8) and lymphoma, all more frequent than in people without HIV
- CD4 200 to 500: oral candidiasis (thrush), oral hairy leukoplakia (EBV), recurrent zoster
- CD4 below 200: Pneumocystis jirovecii pneumonia, progressive multifocal leukoencephalopathy (JC virus), HIV wasting
- CD4 below 150: disseminated histoplasmosis and other endemic mycoses
- CD4 below 100: cerebral toxoplasmosis, cryptococcal meningitis, oesophageal candidiasis, chronic cryptosporidiosis
- CD4 below 50: CMV retinitis and colitis, disseminated Mycobacterium avium complex (MAC), primary CNS lymphoma (EBV)
Risk factors
- Late HIV diagnosis (first presentation with a CD4 count below 200)
- No ART, poor adherence or virological failure
- No prophylaxis when the CD4 count is below the threshold
- Exposure: TB contact or prison, cats and undercooked meat (Toxoplasma), caves, bird or bat droppings and soil work (Histoplasma)
- Positive Toxoplasma IgG, positive serum cryptococcal antigen or latent TB infection
Pathophysiology
HIV infects and destroys CD4 T helper cells → the CD4 count falls year by year without ART → loss of T-cell help disables macrophage activation (interferon-gamma) and cell-mediated immunity → organisms normally held latent by that immunity (Mycobacterium tuberculosis, Toxoplasma cysts, Pneumocystis, Histoplasma, CMV) reactivate or new exposures disseminate → each organism needs a different depth of immune loss, so they appear at predictable CD4 levels → ART suppresses the virus, CD4 cells recover and the risk falls, which is why prophylaxis can be stopped → early after ART starts, the recovering immune system can attack residual organisms and cause immune reconstitution inflammatory syndrome (IRIS).
Classification
- By CD4 band: any count, below 200, below 100, below 50 (see causes)
- Primary prophylaxis: before a first episode, triggered by CD4 count or a positive screening test
- Secondary prophylaxis (maintenance): after a treated episode, to prevent relapse until immune recovery
- AIDS-defining illnesses: PCP, cerebral toxoplasmosis, extrapulmonary cryptococcosis, oesophageal candidiasis, disseminated histoplasmosis or MAC, CMV retinitis, extrapulmonary or pulmonary TB, Kaposi sarcoma, among others
Symptoms and signs
- Subacute dry cough, breathlessness on exertion and fever (PCP)
- Headache, fever, confusion, seizures or focal weakness (toxoplasmosis, cryptococcal meningitis, PML, CNS lymphoma)
- Fever, night sweats, weight loss and cough (TB, histoplasmosis, MAC)
- Painful swallowing (oesophageal candidiasis, CMV or HSV oesophagitis)
- Floaters, flashes or loss of vision (CMV retinitis)
- Chronic watery diarrhoea and wasting (Cryptosporidium, MAC, CMV colitis)
- White plaques in the mouth (thrush) or skin lesions (Kaposi sarcoma, umbilicated papules of histoplasmosis or cryptococcosis)
Diagnosis
- Clinical
- Start with the CD4 count: it shortlists the likely organisms. Combine it with the organ involved and exposures (Colombian setting: always think of TB and histoplasmosis). Ask about ART, adherence and prophylaxis.
- Tests
- CD4 count and HIV viral load; sputum Xpert MTB/RIF and urine LAM for TB; serum cryptococcal antigen (screening when CD4 is below 100, and in meningitis with CSF antigen and opening pressure); Toxoplasma IgG at diagnosis; Histoplasma urine antigen; induced sputum or bronchoalveolar lavage for Pneumocystis; mycobacterial blood cultures for MAC; dilated fundoscopy for CMV with CD4 below 50; IGRA or tuberculin skin test for latent TB.
- Imaging
- Chest X-ray or CT: bilateral ground-glass in PCP, cavities or miliary pattern in TB; brain MRI or contrast CT: multiple ring-enhancing lesions (toxoplasmosis), a single lesion (lymphoma suspicion) or non-enhancing white-matter lesions (PML).
Differential diagnosis
- HIV-associated malignancy (lymphoma, Kaposi sarcoma) instead of infection
- IRIS versus a new opportunistic infection or drug toxicity after starting ART
- Common community infections, which still outnumber opportunistic ones at higher CD4 counts
- Drug reactions (for example to trimethoprim-sulfamethoxazole)
Prophylaxis in HIV: when to start, with what (in principle) and when to stop
| Infection | Primary prophylaxis: start | Drug (principle) | Stop primary | Secondary prophylaxis |
|---|---|---|---|---|
| Pneumocystis (PCP) | CD4 below 200, CD4 below 14%, oral thrush or any AIDS-defining illness | Trimethoprim-sulfamethoxazole; dapsone if intolerant | CD4 200 or more for at least 3 months on ART (or 100 to 200 with an undetectable viral load) | After PCP, same agent and same stop rule |
| Toxoplasma | Positive Toxoplasma IgG with advanced immunodeficiency (Colombian guideline: CD4 below 200; other guidelines use below 100) | Trimethoprim-sulfamethoxazole (also covers PCP); dapsone with pyrimethamine and folinic acid if intolerant | CD4 above 200 on two counts, or 100 to 200 with sustained undetectable viral load | After encephalitis, maintenance until CD4 stays above 200 for months on ART |
| Mycobacterium avium complex (MAC) | Not routine: only CD4 below 50 when ART cannot start within 4 weeks or viraemia persists | A macrolide (azithromycin) | Once ART is effective (CD4 above 100 for 3 months) | After disseminated MAC, maintenance until CD4 above 100 for at least 6 months and no symptoms |
| Cryptococcus | No blind prophylaxis: screen serum cryptococcal antigen when CD4 is below 100; antigen-positive without meningitis gets pre-emptive fluconazole | Fluconazole (itraconazole if contraindicated) | Stop if the antigen result is negative | After meningitis, fluconazole maintenance until CD4 at least 100 with undetectable viral load |
| Tuberculosis | Any CD4: positive IGRA or tuberculin test, close TB contact, or (WHO) every person with HIV once active TB is excluded | TB preventive therapy: isoniazid alone or rifapentine with isoniazid | A fixed course, not CD4-based | Not used: active TB is treated in full and then followed |
Goal of treatment
Treat the active infection, start or optimise ART at the right time, prevent relapse with secondary prophylaxis and prevent new infections with primary prophylaxis until immune recovery.
Treatment
- Medical
- Start ART early in almost every opportunistic infection, usually within two weeks of starting its treatment, because early ART lowers mortality.
- Medical
- Exceptions in timing: in cryptococcal and tuberculous meningitis ART is deferred for some weeks, because early ART raises the risk of fatal IRIS in the closed space of the skull.
- Medical
- Organism-specific treatment: trimethoprim-sulfamethoxazole (with corticosteroids if hypoxaemic) for PCP; pyrimethamine-based or trimethoprim-sulfamethoxazole treatment for toxoplasmosis; amphotericin-based induction then fluconazole for cryptococcosis; standard TB treatment; amphotericin then itraconazole for disseminated histoplasmosis; ganciclovir or valganciclovir for CMV.
- Medical
- Primary and secondary prophylaxis by CD4 count and screening results (see table); TB preventive therapy after active TB is excluded, following Colombia's national TB programme guidelines.
- Follow-up
- CD4 count and viral load to decide when prophylaxis can stop; watch for IRIS (paradoxical worsening after ART) and for drug interactions, especially rifampicin with antiretrovirals.
- Lifestyle
- Prevention of exposure: avoid undercooked meat and cat litter (Toxoplasma), cave and bird-dropping exposure (Histoplasma), untreated water (Cryptosporidium); vaccination against pneumococcus, hepatitis B, influenza and others as indicated.
Complications
- Death: opportunistic infections remain the main cause of death in people with advanced HIV
- Immune reconstitution inflammatory syndrome (paradoxical or unmasking)
- Blindness from CMV retinitis
- Neurological sequelae after toxoplasmosis, cryptococcal meningitis or PML
- Drug toxicity and interactions from multiple treatments
Common traps
- Opportunistic infections only appear when CD4 is below 200: TB, pneumococcal pneumonia and zoster occur at any CD4 count, and TB is the commonest of all
- Once on prophylaxis, always on prophylaxis: primary and secondary prophylaxis are stopped when ART keeps CD4 above the threshold for months with a suppressed viral load
- ART should always wait until the infection is cured: most opportunistic infections do better with ART within two weeks; the exception is meningitis (cryptococcal, tuberculous), where early ART raises fatal IRIS
- A negative chest X-ray rules out PCP: the film can be normal early; low exercise saturation and a high LDH point to it, and CT or lavage confirm it
- Ring-enhancing brain lesions in AIDS are always toxoplasmosis: a single lesion, negative Toxoplasma IgG or no response to treatment points to primary CNS lymphoma or TB
Prognosis
Outcome depends mainly on how early the infection is recognised and whether ART restores immunity. With effective ART and completed treatment, most people recover and can stop prophylaxis; late diagnosis with cryptococcal meningitis, disseminated histoplasmosis or TB still carries high mortality.
Prevention
- HIV testing so that diagnosis is early, followed by immediate ART for everyone
- Prophylaxis by CD4 count: trimethoprim-sulfamethoxazole below 200, cryptococcal antigen screening below 100
- TB screening at every visit and TB preventive therapy once active TB is excluded
- Toxoplasma IgG at diagnosis; itraconazole in high-risk exposure with CD4 below 150 in hyperendemic areas (Colombian guideline)
- Do not give routine primary prophylaxis against candida or CMV
Test yourself
Think of the answer, then tap the question to see it.
Which prophylaxis covers both Pneumocystis and Toxoplasma, and what is the main CD4 threshold for Pneumocystis?
Trimethoprim-sulfamethoxazole covers both; Pneumocystis prophylaxis starts when CD4 is below 200 (or below 14%, or with thrush or an AIDS-defining illness).
Why is serum cryptococcal antigen measured in people with CD4 below 100 who feel well?
Antigen appears weeks before meningitis; finding it allows pre-emptive fluconazole (after a lumbar puncture excludes meningitis) and prevents a disease with high mortality.
A 34-year-old newly diagnosed with HIV (CD4 35) has fever, weight loss, pancytopenia and umbilicated skin papules after cave tourism in Santander. Likely diagnosis and quick test?
Disseminated histoplasmosis, a common AIDS-defining illness in Latin America often mistaken for TB. Urine Histoplasma antigen is fast; blood or bone-marrow culture and skin biopsy confirm it.
Why is ART deferred for some weeks in cryptococcal meningitis but not in PCP?
Early ART in meningitis triggers IRIS inside the rigid skull, raising mortality; in PCP and most other infections, ART within two weeks lowers mortality.
When can PCP prophylaxis be stopped?
When ART keeps the CD4 count at 200 or more for at least three months (or 100 to 200 with an undetectable viral load).
Why it happens
- HIV in the brain and PML
- The lung in immunocompromise and transplant
- Fungal infections of the CNS
- Parasitic brain infections
Connections
In physiology1
Educational information, not medical advice. For any symptom, see a health professional.
Sources: HIV-1–Associated Opportunistic Infections (StatPearls (NCBI Bookshelf), 2026); Guía de Práctica Clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH/SIDA en personas adultas, gestantes y adolescentes (Ministerio de Salud y Protección Social (Colombia), 2021); Resolución 227 de 2020 (Ministerio de Salud y Protección Social (Colombia), 2020); HIV and AIDS (World Health Organization, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.

